GlassScriptPhysician profile
Peter Steven Heyman
NPI 1114953569
$3,120.27
in general payments reported to CMS, 2019-2025
27 companies · $374 in 2025
The $374 reported for 2025 was more than what 88% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $649 · 2021: $206 · 2022: $443 · 2023: $483 · 2024: $640 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $500.00 | 2020 | |
| Corium, LLC | $396.84 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $256.57 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $235.29 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $216.53 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $195.11 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Kaleo, INC. | $187.74 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $179.22 | 2019-2024 | |
| Neos Therapeutics, LP | $148.93 | 2020-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Tris Pharma INC | $124.28 | 2019-2022 | |
| Seqirus USA INC | $117.74 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Greer Laboratories, INC. | $109.81 | 2025 | Oralair |
| Cranial Technologies, INC | $74.02 | 2019-2022 | |
| Smith+Nephew, INC. | $42.44 | 2019 | |
| Verrica Pharmaceuticals INC. | $38.89 | 2024 | Ycanth |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $38.83 | 2019-2025 | Pediarix, Bexsero |
| Collegium Pharmaceutical, INC. | $34.43 | 2025 | Jornay Pm |
| Ars Pharmaceuticals Operations, INC. | $29.13 | 2025 | Neffy |
| Sobi, INC | $28.39 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.38 | 2019-2021 | |
| Shire North American Group INC | $26.78 | 2019 | |
| Alk-Abello, INC | $24.89 | 2024 | Odactra, Ragwitek, Grastek |
| Phadia US INC. | $21.02 | 2019 | |
| Lnhc, INC | $20.00 | 2025 | Zelsuvmi |
| Roche Diagnostics Corporation | $19.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.53 | 2019 | |
| Genentech USA, INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Heyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.